NCT03358472 2025-12-03Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)Incyte CorporationPhase 3 Completed89 enrolled 14 charts